ZVRA
NASDAQ · Pharmaceuticals
Zevra Therapeutics Inc
$10.26
+0.16 (+1.58%)
Financial Highlights (FY 2026)
Revenue
125.88M
Net Income
98.41M
Gross Margin
96.4%
Profit Margin
78.2%
Rev Growth
+116.7%
D/E Ratio
0.40
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 96.4% | 73.6% | 67.4% | 67.4% |
| Operating Margin | -59.1% | -331.6% | 38.2% | 37.7% |
| Profit Margin | 78.2% | -424.5% | 22.3% | 21.7% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 125.88M | 30.86M | 109.96M | 97.45M |
| Gross Profit | 121.31M | 22.71M | 74.11M | 65.67M |
| Operating Income | -74,421,044 | -102,327,889 | 41.96M | 36.73M |
| Net Income | 98.41M | -124,101,933 | 24.47M | 21.13M |
| Gross Margin | 96.4% | 73.6% | 67.4% | 67.4% |
| Operating Margin | -59.1% | -331.6% | 38.2% | 37.7% |
| Profit Margin | 78.2% | -424.5% | 22.3% | 21.7% |
| Rev Growth | +116.7% | -6.2% | -4.5% | -6.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 99.31M | 152.51M | 183.66M | 151.32M |
| Total Equity | 248.01M | 101.67M | 340.87M | 348.61M |
| D/E Ratio | 0.40 | 1.50 | 0.54 | 0.43 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -69,626,398 | -97,531,026 | 54.29M | 55.97M |
| Free Cash Flow | — | — | 22.49M | 20.93M |